Skip to main content
Erschienen in: Heart and Vessels 12/2018

15.05.2018 | Short Communication

Electrocardiographic and echocardiographic findings in muscular dystrophy patients with heart failure

verfasst von: Masataka Ogiso, Toshiaki Isogai, Ken Kato, Hiroyuki Tanaka, Tamotsu Tejima, Eiji Isozaki

Erschienen in: Heart and Vessels | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Cardiac involvement in muscular dystrophy (MD) is known to cause heart failure (HF). However, little is known about the differences in electrocardiographic and echocardiographic findings between MD patients with and without the experience of hospitalization for HF. We retrospectively identified 95 MD patients (mean age at diagnosis of MD 41.1 ± 18.7 years; males 64.2%), including nine (9.4%) patients who were hospitalized for HF (the HF group) and 86 (90.6%) patients who were not (the non-HF group) during the follow-up period (16.7 ± 12.2 years). The HF group had a significantly wider QRS duration (126.0 ± 37.6 vs. 98.1 ± 16.7 ms, p < 0.001) and QTc interval (454.6 ± 50.5 vs. 409.5 ± 23.6 ms, p < 0.001) at the time of HF hospitalization than the non-HF group. The HF group also had a significantly lower left ventricular (LV) ejection fraction (35.4 ± 19.2 vs. 62.5 ± 11.3%, p < 0.001) and significantly larger diastolic LV dimension (64 ± 2 vs. 45 ± 1 mm, p < 0.001) and left atrial diameter (38 ± 12 vs. 29 ± 6 mm, p = 0.003) at the time of HF hospitalization than the non-HF group. In the HF group, the QRS duration was significantly wider at the time of HF hospitalization than at the initial electrocardiogram before the development of HF (129.8 ± 30.7 vs. 119.0 ± 33.3 ms, p = 0.018). This study suggests that HF occurs in MD patients with electrocardiographic and echocardiographic abnormalities. Early recognition of abnormal findings during a regular electrocardiographic or echocardiographic follow-up may be useful for identifying cardiac involvement in MD.
Literatur
1.
Zurück zum Zitat Kamdar F, Garry DJ (2016) Dystrophin-deficient cardiomyopathy. J Am Coll Cardiol 67:2533–2546CrossRef Kamdar F, Garry DJ (2016) Dystrophin-deficient cardiomyopathy. J Am Coll Cardiol 67:2533–2546CrossRef
2.
3.
Zurück zum Zitat Spurney CF (2011) Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions. Muscle Nerve 44:8–19CrossRef Spurney CF (2011) Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions. Muscle Nerve 44:8–19CrossRef
4.
Zurück zum Zitat Fayssoil A, Ogna A, Chaffaut C, Chevret S, Guimaraes-Costa R, Leturcq F, Wahbi K, Prigent H, Lofaso F, Nardi O, Clair B, Behin A, Stojkovic T, Laforet P, Orlikowski D, Annane D (2016) Natural history of cardiac and respiratory involvement, prognosis and predictive factors for long-term survival in adult patients with limb girdle muscular dystrophies type 2C and 2D. PLoS One 11:e0153095CrossRef Fayssoil A, Ogna A, Chaffaut C, Chevret S, Guimaraes-Costa R, Leturcq F, Wahbi K, Prigent H, Lofaso F, Nardi O, Clair B, Behin A, Stojkovic T, Laforet P, Orlikowski D, Annane D (2016) Natural history of cardiac and respiratory involvement, prognosis and predictive factors for long-term survival in adult patients with limb girdle muscular dystrophies type 2C and 2D. PLoS One 11:e0153095CrossRef
5.
Zurück zum Zitat Matsumura T, Saito T, Fujimura H, Shinno S, Sakoda S (2011) A longitudinal cause-of-death analysis of patients with Duchenne muscular dystrophy. Rinsho Shinkeigaku 51:743–750CrossRef Matsumura T, Saito T, Fujimura H, Shinno S, Sakoda S (2011) A longitudinal cause-of-death analysis of patients with Duchenne muscular dystrophy. Rinsho Shinkeigaku 51:743–750CrossRef
6.
Zurück zum Zitat Kimura K, Takenaka K, Ebihara A, Uno K, Morita H, Nakajima T, Ozawa T, Aida I, Yonemochi Y, Higuchi S, Motouoshi Y, Mikata T, Uchida I, Ishihara T, Komori T, Kitao R, Nagata T, Takeda S, Yatomi Y, Nagai R, Komuro I (2013) Prognostic impact of left ventricular noncompaction in patients with Duchenne/Becker muscular dystrophy—prospective multicenter cohort study. Int J Cardiol 168:1900–1904CrossRef Kimura K, Takenaka K, Ebihara A, Uno K, Morita H, Nakajima T, Ozawa T, Aida I, Yonemochi Y, Higuchi S, Motouoshi Y, Mikata T, Uchida I, Ishihara T, Komori T, Kitao R, Nagata T, Takeda S, Yatomi Y, Nagai R, Komuro I (2013) Prognostic impact of left ventricular noncompaction in patients with Duchenne/Becker muscular dystrophy—prospective multicenter cohort study. Int J Cardiol 168:1900–1904CrossRef
7.
Zurück zum Zitat Kimura K, Morita H, Nakamura A, Takenaka K, Daimon M (2016) Therapeutic strategy for heart failure in becker muscular dystrophy. Int Heart J 57:527–529CrossRef Kimura K, Morita H, Nakamura A, Takenaka K, Daimon M (2016) Therapeutic strategy for heart failure in becker muscular dystrophy. Int Heart J 57:527–529CrossRef
8.
Zurück zum Zitat Japanese Society of neurology (2014) Practical guideline for Duchenne muscular dystrophy (DMD) 2014. Nannkodo, pp 1–200 Japanese Society of neurology (2014) Practical guideline for Duchenne muscular dystrophy (DMD) 2014. Nannkodo, pp 1–200
9.
Zurück zum Zitat Nieminen MS, Harjola VP (2005) Definition and epidemiology of acute heart failure syndromes. Am J Cardiol 96:5G–10GCrossRef Nieminen MS, Harjola VP (2005) Definition and epidemiology of acute heart failure syndromes. Am J Cardiol 96:5G–10GCrossRef
10.
Zurück zum Zitat Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, Cammann VL, Sarcon A, Geyer V, Neumann CA, Seifert B, Hellermann J, Schwyzer M, Eisenhardt K, Jenewein J, Franke J, Katus HA, Burgdorf C, Schunkert H, Moller C, Thiele H, Bauersachs J, Tschope C, Schultheiss HP, Laney CA, Rajan L, Michels G, Pfister R, Ukena C, Bohm M, Erbel R, Cuneo A, Kuck KH, Jacobshagen C, Hasenfuss G, Karakas M, Koenig W, Rottbauer W, Said SM, Braun-Dullaeus RC, Cuculi F, Banning A, Fischer TA, Vasankari T, Airaksinen KEJ, Fijalkowski M, Rynkiewicz A, Pawlak M, Opolski G, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Galiuto L, Crea F, Dichtl W, Frantz WM, Empen K, Felix SB, Delmas C, Lairez O, Erne P, Bax JJ, Ford I, Ruschitzka F, Prasad A, Luscher TF (2015) Clinical features and outcomes of takotsubo (stress) cardiomyopathy. N Engl J Med 373:929–938CrossRef Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, Cammann VL, Sarcon A, Geyer V, Neumann CA, Seifert B, Hellermann J, Schwyzer M, Eisenhardt K, Jenewein J, Franke J, Katus HA, Burgdorf C, Schunkert H, Moller C, Thiele H, Bauersachs J, Tschope C, Schultheiss HP, Laney CA, Rajan L, Michels G, Pfister R, Ukena C, Bohm M, Erbel R, Cuneo A, Kuck KH, Jacobshagen C, Hasenfuss G, Karakas M, Koenig W, Rottbauer W, Said SM, Braun-Dullaeus RC, Cuculi F, Banning A, Fischer TA, Vasankari T, Airaksinen KEJ, Fijalkowski M, Rynkiewicz A, Pawlak M, Opolski G, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Galiuto L, Crea F, Dichtl W, Frantz WM, Empen K, Felix SB, Delmas C, Lairez O, Erne P, Bax JJ, Ford I, Ruschitzka F, Prasad A, Luscher TF (2015) Clinical features and outcomes of takotsubo (stress) cardiomyopathy. N Engl J Med 373:929–938CrossRef
11.
Zurück zum Zitat JCS Joint Working Group (2013) Guidelines for non-pharmacotherapy of cardiac arrhythmias (JCS 2011). Circ J 77:249–274CrossRef JCS Joint Working Group (2013) Guidelines for non-pharmacotherapy of cardiac arrhythmias (JCS 2011). Circ J 77:249–274CrossRef
12.
Zurück zum Zitat Ilkhanoff L, Liu K, Ning H, Nazarian S, Bluemke D, Soliman E, Lloyd-Jones D (2012) Association of QRS duration with left ventricular structure and function and risk of heart failure in middle-aged and older adults: the multi-ethnic study of atherosclerosis (MESA). Eur J Heart Fail 14:1285–1292CrossRef Ilkhanoff L, Liu K, Ning H, Nazarian S, Bluemke D, Soliman E, Lloyd-Jones D (2012) Association of QRS duration with left ventricular structure and function and risk of heart failure in middle-aged and older adults: the multi-ethnic study of atherosclerosis (MESA). Eur J Heart Fail 14:1285–1292CrossRef
13.
Zurück zum Zitat Yamada T, Shimonagata T, Misaki N, Asai M, Makino N, Kioka H, Tamaki S, Fukunami M (2004) Usefulness of spatial dispersion of QRS duration in predicting mortality in patients with mild to moderate chronic heart failure. Am J Cardiol 94:960–963CrossRef Yamada T, Shimonagata T, Misaki N, Asai M, Makino N, Kioka H, Tamaki S, Fukunami M (2004) Usefulness of spatial dispersion of QRS duration in predicting mortality in patients with mild to moderate chronic heart failure. Am J Cardiol 94:960–963CrossRef
14.
Zurück zum Zitat Yamaguchi T, Yoshikawa T, Isogai T, Miyamoto T, Maekawa Y, Ueda T, Sakata K, Murakami T, Yamamoto T, Nagao K, Takayama M (2016) Predictive value of QRS duration at admission for in-hospital clinical outcome of Takotsubo cardiomyopathy. Circ J 81:62–68CrossRef Yamaguchi T, Yoshikawa T, Isogai T, Miyamoto T, Maekawa Y, Ueda T, Sakata K, Murakami T, Yamamoto T, Nagao K, Takayama M (2016) Predictive value of QRS duration at admission for in-hospital clinical outcome of Takotsubo cardiomyopathy. Circ J 81:62–68CrossRef
15.
Zurück zum Zitat Cantor AA, Goldfarb B, Ilia R (2000) QRS prolongation: a sensitive marker of ischemia during percutaneous transluminal coronary angioplasty. Catheter Cardiovasc interv 50:177–183CrossRef Cantor AA, Goldfarb B, Ilia R (2000) QRS prolongation: a sensitive marker of ischemia during percutaneous transluminal coronary angioplasty. Catheter Cardiovasc interv 50:177–183CrossRef
16.
Zurück zum Zitat Gilmour RF Jr, Evans JJ, Zipes DP (1984) Purkinje-muscle coupling and endocardial response to hyperkalemia, hypoxia, and acidosis. Am J Physiol 247:H303–H311PubMed Gilmour RF Jr, Evans JJ, Zipes DP (1984) Purkinje-muscle coupling and endocardial response to hyperkalemia, hypoxia, and acidosis. Am J Physiol 247:H303–H311PubMed
17.
Zurück zum Zitat Finsterer J, Stollberger C (2008) Cardiac involvement in Becker muscular dystrophy. Can J Cardiol 24:786–792CrossRef Finsterer J, Stollberger C (2008) Cardiac involvement in Becker muscular dystrophy. Can J Cardiol 24:786–792CrossRef
18.
Zurück zum Zitat Orlov YS, Brodsky MA, Allen BJ, Ott RA, Orlov MV, Jay CA (1994) Cardiac manifestations and their management in Becker’s muscular dystrophy. Am Heart J 128:193–196CrossRef Orlov YS, Brodsky MA, Allen BJ, Ott RA, Orlov MV, Jay CA (1994) Cardiac manifestations and their management in Becker’s muscular dystrophy. Am Heart J 128:193–196CrossRef
19.
Zurück zum Zitat Angelini C, Fanin M, Freda MP, Martinello F, Miorin M, Melacini P, Siciliano G, Pegoraro E, Rosa M, Danieli GA (1996) Prognostic factors in mild dystrophinopathies. J Neurol Sci 142:70–78CrossRef Angelini C, Fanin M, Freda MP, Martinello F, Miorin M, Melacini P, Siciliano G, Pegoraro E, Rosa M, Danieli GA (1996) Prognostic factors in mild dystrophinopathies. J Neurol Sci 142:70–78CrossRef
20.
Zurück zum Zitat Rapezzi C, Leone O, Biagini E, Coccolo F (2007) Echocardiographic clues to diagnosis of dystrophin related dilated cardiomyopathy. Heart 93:10CrossRef Rapezzi C, Leone O, Biagini E, Coccolo F (2007) Echocardiographic clues to diagnosis of dystrophin related dilated cardiomyopathy. Heart 93:10CrossRef
21.
Zurück zum Zitat Mori-Yoshimura M, Segawa K, Minami N, Oya Y, Komaki H, Nonaka I, Nishino I, Murata M (2017) Cardiopulmonary dysfunction in patients with limb-girdle muscular dystrophy 2A. Muscle Nerve 55:465–469CrossRef Mori-Yoshimura M, Segawa K, Minami N, Oya Y, Komaki H, Nonaka I, Nishino I, Murata M (2017) Cardiopulmonary dysfunction in patients with limb-girdle muscular dystrophy 2A. Muscle Nerve 55:465–469CrossRef
22.
Zurück zum Zitat Groen EJ, Charlton R, Barresi R, Anderson LV, Eagle M, Hudson J, Koref MS, Straub V, Bushby KM (2007) Analysis of the UK diagnostic strategy for limb girdle muscular dystrophy 2A. Brain 130:3237–3249CrossRef Groen EJ, Charlton R, Barresi R, Anderson LV, Eagle M, Hudson J, Koref MS, Straub V, Bushby KM (2007) Analysis of the UK diagnostic strategy for limb girdle muscular dystrophy 2A. Brain 130:3237–3249CrossRef
23.
Zurück zum Zitat Nigro G, Comi LI, Politano L, Bain RJ (1990) The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 26:271–2717CrossRef Nigro G, Comi LI, Politano L, Bain RJ (1990) The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 26:271–2717CrossRef
24.
Zurück zum Zitat Spurney C, Shimizu R, Morgenroth LP, Hache LP, Kolski H, Gordish-Dressman H, Clemens PR, The CINRG Investigators (2014) Cooperative International Neuromuscular Research Group Duchenne Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy. Muscle Nerve 50:250–256CrossRef Spurney C, Shimizu R, Morgenroth LP, Hache LP, Kolski H, Gordish-Dressman H, Clemens PR, The CINRG Investigators (2014) Cooperative International Neuromuscular Research Group Duchenne Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy. Muscle Nerve 50:250–256CrossRef
25.
Zurück zum Zitat JCS Joint Working Group (2013) Guidelines for treatment of acute heart failure (JCS 2011). Circ J 77:2157–2201CrossRef JCS Joint Working Group (2013) Guidelines for treatment of acute heart failure (JCS 2011). Circ J 77:2157–2201CrossRef
26.
Zurück zum Zitat Bonilla-Palomas JL, Gamez-Lopez AL, Moreno-Conde M, Lopez-Ibanez MC, Anguita-Sanchez M, Gallego de la Sacristana A, Garcia-Catalan F, Villar-Raez A (2014) Hypoalbuminemia in acute heart failure patients: causes and its impact on hospital and long-term mortality. J Card Fail 20:350–358CrossRef Bonilla-Palomas JL, Gamez-Lopez AL, Moreno-Conde M, Lopez-Ibanez MC, Anguita-Sanchez M, Gallego de la Sacristana A, Garcia-Catalan F, Villar-Raez A (2014) Hypoalbuminemia in acute heart failure patients: causes and its impact on hospital and long-term mortality. J Card Fail 20:350–358CrossRef
28.
Zurück zum Zitat Ogata H, Ishikawa Y, Ishikawa Y, Minami R (2009) Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy. J Cardiol 53:72–78CrossRef Ogata H, Ishikawa Y, Ishikawa Y, Minami R (2009) Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy. J Cardiol 53:72–78CrossRef
29.
Zurück zum Zitat Viollet L, Thrush PT, Flanigan KM, Mendell JR, Allen HD (2012) Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. Am J Cardiol 110:98–102CrossRef Viollet L, Thrush PT, Flanigan KM, Mendell JR, Allen HD (2012) Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. Am J Cardiol 110:98–102CrossRef
30.
Zurück zum Zitat Rhodes J, Margossian R, Darras BT, Colan SD, Jenkins KJ, Geva T, Powell AJ (2008) Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. Pediatr Cardiol 29:343–351CrossRef Rhodes J, Margossian R, Darras BT, Colan SD, Jenkins KJ, Geva T, Powell AJ (2008) Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. Pediatr Cardiol 29:343–351CrossRef
31.
Zurück zum Zitat De Benedittis G, Rosa GD, D’Ettorre E, Piscitelli P, Distante A, de Gregorio C (2016) Effect of Ivabradine in dilated cardiomyopathy from Duchenne muscular dystrophy: a chance for slowing progression of heart failure? Int J Cardiol 223:286–288CrossRef De Benedittis G, Rosa GD, D’Ettorre E, Piscitelli P, Distante A, de Gregorio C (2016) Effect of Ivabradine in dilated cardiomyopathy from Duchenne muscular dystrophy: a chance for slowing progression of heart failure? Int J Cardiol 223:286–288CrossRef
Metadaten
Titel
Electrocardiographic and echocardiographic findings in muscular dystrophy patients with heart failure
verfasst von
Masataka Ogiso
Toshiaki Isogai
Ken Kato
Hiroyuki Tanaka
Tamotsu Tejima
Eiji Isozaki
Publikationsdatum
15.05.2018
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 12/2018
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-018-1186-5

Weitere Artikel der Ausgabe 12/2018

Heart and Vessels 12/2018 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.